ANRO•benzinga•
Alto Neuroscience Says Based On Results Of Interim Analysis, ALTO-300 Phase 2b Trial Will Continue With An increase Of ~50 Biomarker Positive Patients, With Topline Results Expected In Mid 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga